Oravital Inc. Launching its BiofilmDNA® Oral Microbial Salivary Test During its Chicago Midwinter Meeting Debut

New Diagnostic Test Provides a Whole-Mouth Picture of Patient’s Oral Health

Toronto, CA – February 8, 2016 – Oravital Inc., the manufacturer of the Oravital^® System for the diagnosis and treatment of periodontal disease and halitosis, will be making its debut at the Chicago Midwinter Dental Meeting at the McCormick Convention Center at booth #4537 from February 25^th  through February 27^th.  During this time, the company will also unveil its latest weapon in the war against oral infections – the BiofilmDNA^® oral microbial salivary test.

BiofilmDNA^® is a highly-sensitive DNA test that detects both the presence and thresholds of specific pathogens via the collection of salivary, subgingival, and tongue biofilm samples. This advanced and accurate biofilm analysis provides the dental clinician with a detailed, multi-panel, whole-mouth picture of the patient’s oral health.

Oravital’s new BiofilmDNA^® test is a powerful compliment to its BiofilmGS^® test, which uses site-specific Gram stain analysis to determine the exact type and location of oral infection. Both the BiofilmDNA^® and BiofilmGS^® tests are analyzed in Oravital’s on-site, state-of-the-art lab facility, with reports available within two days of receiving the samples. Used together, the two biofilm tests will help the dental clinician accurately identify the following:

·       Periodontal disease pathogens

·       Opportunistic parasites

·       Caries pathogens

·       Yeasts

·       Inflammatory response

According to company president and CEO Dr. Jim Hyland, “The Oravital^® System effectively closes the diagnosis/treatment loop by identifying the exact cause and location of oral infection, then providing a highly-effective regimen of antibiotic and antimicrobial rinses specifically prescribed for the patient’s personal diagnosis.”

Throughout the Chicago Midwinter Meeting, Oravital^® will be offering the BiofilmDNA^® test for an introductory price of $75.00 each for the first 10 tests (Regularly $85.00 each). Which is a $100.00 savings! In addition, dentist can sign up their teams for the Oravital Platinum Coaching Package for $995.00 (normally $1,295.00) and save $300.00. In addition, there will be a drawing for a free iPad Mini.

Dr. Hyland, DDS BSc, and his clinical management team consisting of Chief Science Officer Anne Bosy, RRDH, MEd, MSc, and Clinical Hygiene Educator Kerry Lepicek, RDH, will be on hand to explain the efficacy and application of the proprietary Oravital^® System, which consists of the following five steps:

1.    Diagnosis

2.    Treatment

3.    Evaluation  

4.    Maintenance

5.    Monitoring

“Undiagnosed and untreated oral infections are a North American epidemic,” explains Hyland. “We also know that periodontal disease is a contributing factor to many systemic conditions such as cardiovascular disease, diabetes, and Alzheimer’s disease, because the infection spreads via both tissues and the blood stream. With the introduction of BiofilmDNA^®, now more than ever, the Oravital^® system can have a positive impact on not just the oral health, but the overall health of the patient.”

For more information on the Oravital^® System and how your dental practice can become a Certified Oravital^® Clinic, visit www.oravital.com or call 1-800-909-6468.

About Oravital Inc.

Oravital Inc. was established in the fall of 2007 in Toronto, Canada. The company licenses proprietary technology called the Oravital^® System to certified dental clinics throughout North America for the most advanced, effective and painless diagnosis and treatment of oral infections available today.

With recent studies linking oral infections with systemic conditions such as heart disease and diabetes, periodontal disease is now considered a medical condition that dental professionals should treat. What’s more, given that 75% of the population continues to have signs of periodontal disease in spite of our best efforts, diagnosis and predictable treatment of this infection has become extremely important.   

Oravital’s proprietary protocol of inexpensive biofilm testing and the use of prescribed antibiotic and antimicrobial rinses dramatically halt the progress of periodontal disease and breath odor.  Bleeding is reduced by 87%, and pocket depths shrink by 76 to 84% within a few weeks. Oravital^® proprietary rinses treat the entire oral complex and are non-systemic.  The Oravital^® System is the only system to predictably treat the oral-systemic link.

The science of Oravital^® evolved from 15 years of ground-breaking research and successful clinical treatment by Anne Bosy, RRDH, MEd, MSc, co-founder of Toronto's Fresh Breath Clinic. Dr. Walter Loesche, who was a respected authority on periodontal disease treatment at the University of Michigan, validated the effectiveness of the antibiotic therapy developed by Anne Bosy.  

Oravital Inc. also provides a comprehensive, dynamic and scientifically-grounded training program to its certified clinics. Oravital^® certified dental professionals are authorized experts in providing Oravital^® diagnostic analysis, individualized treatment, and dedicated long-term support. For more information, visit www.oravital.com or call 1-800-909-6468.

# # #